Segmentectomy for Solid-dominant Lung Cancer
Recruiting
Phase 3
Interventional Study
Segmentectomy
Lung Adenocarcinoma
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Pivotal Trial
This treatment is in the last trial phase before FDA approval.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 – 80
- Sex
- Any
- Trial phase
- Phase 3
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 277 (estimated)
- Sponsor
- Fudan University · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This is a clinical trial from Eastern Cooperative Thoracic Oncology Project (ECTOP), numbered as ECTOP-1025. The goal of this clinical trial is to confirm the theraputic effect of segmentectomy for solid-dominant invasive lung cancer with size of 2-3cm. The main questions it aims to answer are:
* The 5-year disease-free survival of patients having solid-dominant invasive lung cancer with size of …
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Patients who sign the informed consent form and are willing to complete the study according to the plan;
* Aged from 18 to 80 years old;
* ECOG equals 0 or 1;
* Not receiving lung cancer surgery before;
* Confirmed to be invasive lung adenocarcinoma intraoperatively or postope…
Contacts